[Antiparkinsonian drugs].
Levodopa (+ dopa decarboxylase inhibitor) is the most active of all drugs used in the treatment of Parkinson's disease. It acts on both akinesia and rigidity and improves the prognosis of the disease by increasing life expectancy. But levodopa also produces late side-effects: it often induces abnormal movements, fluctuations in motor performance, on-off effects, psychotic hallucinations, etc. Since these late side-effects remain difficult to treat, it is always necessary to assess the benefits and risks of the first treatment with levodopa. Anticholinergic drugs, which mainly act on tremor, must be used with caution since they may induce memory alterations and often confusional states in aged parkinsonians. Dopamine agonists are prescribed as adjuvant therapy in the treatment of the late side-effects of levodopa. New drugs (selegiline), new pharmaceutical preparations (sustained release forms), the first treatment of the disease (levodopa alone versus agonists alone versus levodopa + agonists), together with the new pharmacological approaches (brain grafts, drug infusions) are now under clinical evaluation.
Rascol
A
A
Montastruc
J L
JL
Rascol
O
O
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D004298:Dopamine / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D010276:Parasympatholytics; D007980:Levodopa; D004298:Dopamine
Les médicaments antiparkinsoniens.